As opposed to ER/PR-positive and HER2-positive breast cancers, few new treatment options have emerged for TNBC, resulting in little improvement in overall survival rates over the past 20–30 years compared to other cancers [5]. This evidence concerns the gene ESR1 and breast carcinoma.